Sensei Biotherapeutics reports 50% 6-month PFS for solnerstotug in PD-(L)1 resistant tumors at ESMO 2025

Sensei Biotherapeutics, Inc.

6-month PFS of 50% in 15 mg/kg dose cohort in PD-(L)1 resistant patients vs historical ~10-20% for docetaxel.
Complete response in Merkel cell carcinoma patient; duration of response 54+ weeks. Four of six responders had late onset responses (18-54 weeks).
Favorable safety: only six mild Grade 1 CRS events across all 98 patients; no new safety signals.
Phase 2 studies planned in 2L NSCLC and Merkel cell carcinoma in 2026, subject to FDA feedback and capital raise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.